MedTrace Logo

Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT05162872 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2021-12-17

No results posted yet for this study

Summary

this study is aimed to evaluate the efficacy and safety of the combination of Niraparib and Sintilimab in the treatment of recurrent/metastatic nasopharyngeal carcinoma

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Niraparib，Sintilimab

Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Li zhang, DOCTOR · SUN YAT-SEN UNVERISITY CANCER CENTER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-05
Primary Completion
2023-06-30
Completion
2023-10-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05162872 on ClinicalTrials.gov